GlassScriptPhysician profile
Molly Beth Delk
NPI 1679967236
$3,676.10
in general payments reported to CMS, 2019-2025
20 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $390 · 2021: $526 · 2022: $598 · 2023: $98.98 · 2024: $682 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,088.53 | 2020-2025 | Livdelzi |
| Abbvie INC. | $420.69 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $414.43 | 2024-2025 | Iqirvo, Bylvay |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.06 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $259.71 | 2020-2023 | Entyvio |
| Janssen Biotech, INC. | $255.71 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $249.99 | 2019 | |
| Mallinckrodt Hospital Products INC. | $149.20 | 2025 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $115.55 | 2022 | |
| Boston Scientific Corporation | $95.08 | 2022 | |
| Intercept Pharmaceuticals, INC. | $70.65 | 2021-2025 | |
| Eisai INC. | $54.80 | 2019-2020 | |
| Veloxis Pharmaceuticals, INC. | $32.87 | 2025 | |
| Mirum Pharmaceuticals, INC. | $24.62 | 2023 | Livmarli |
| Pfizer INC. | $19.87 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $18.35 | 2020 | |
| Novo Nordisk INC | $16.90 | 2025 | Wegovy |
| Shire North American Group INC | $16.09 | 2019 | |
| Erbe USA INC | $15.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Delk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.